No tax




Security policy (edit with Customer reassurance module)


Delivery policy (edit with Customer reassurance module)


Return policy (edit with Customer reassurance module)

Mechanism of action

Chondroitin sulfate is the main component of proteoglycans that make up the cartilage matrix together with collagen fibers.

It has chondrostimulating, regenerating, anti-inflammatory and analgesic effects. Chondroitin sulfate is involved in the construction of the main substance of cartilage and bone tissue. It has chondroprotective properties; enhances metabolic processes in hyaline and fibrous cartilage and subchondral bone; inhibits the activity of enzymes that cause degradation (destruction) of articular cartilage; stimulates the production of chondrocyte proteoglycans; It has an effect on Calcium and phosphorus metabolism in cartilage, stimulates its regeneration, and participates in the construction of the main substance of bone and cartilage tissue. It has anti-inflammatory and analgesic properties, helps reduce the release into the synovial fluid of inflammatory mediators and pain factors through synoviocytes and synovial macrophages, and suppresses the secretion of leukotrienes and prostaglandins. The drug prevents the degeneration of connective tissue and reduces calcium loss, accelerates bone tissue repair processes.

Chondroitin sulfate slows the progression of osteoarthritis and osteochondrosis. It contributes to the restoration of the articular sac and the cartilaginous surfaces of the joints, prevents the collapse of connective tissue, normalizes the production of articular fluid.

The clinical effect is manifested by an improvement in the mobility of the joints, a decrease in the intensity of pain, while the therapeutic effect persists for a long time after the end of the course of therapy. In the treatment of degenerative changes in the joints, accompanied by secondary synovitis, the effect is observed after 2-3 weeks from the start of the course.

Possessing structural similarity with Heparin, it can potentially interfere with the formation of fibrin clots in the synovial and subchondral microvascular bed.


Suction and distribution

Chondroitin sodium sulfate is easily absorbed with the / m introduction. 30 minutes after i / m administration, it is found in the blood in significant concentrations; after 15 min - in the synovial fluid. Cmaxin the blood plasma is reached after 1 h after injection, then the concentration of the drug gradually decreases over 2 days.

Accumulates mainly in cartilage tissue (Cmax in articular cartilage is achieved after 48 h); synovial membrane is not an obstacle to the penetration of the drug into the joint cavity.


Excreted mainly by the kidneys within 24 hours.


Degenerative-dystrophic diseases of the joints and spine:

- Osteoarthritis of the peripheral joints;

- intervertebral osteochondrosis and osteoarthrosis.

To accelerate the formation of callus in fractures.

Dosage and administration

V / m, 1 ml every other day. With good portability, increase the dose to 2 ml, starting with the fourth injection. The course of treatment is 25-35 injections. If necessary, after 6 months, it is possible to repeat the course of treatment. The duration of repeated courses of treatment is determined by the doctor.

For the formation of callus The course of treatment is 3-4 weeks (10-14 injections every other day).

Side effect

When using the drug in individuals with hypersensitivity to the drug, the following disorders are possible.

Immune system:allergic reactions, angioedema.

On the part of the skin and subcutaneous fat:skin rash, itching, erythema, urticaria, dermatitis.

Gastrointestinal: dyspeptic phenomena.

Local reactions: redness, itching, hemorrhages are possible at the injection site.


- Hypersensitivity to chondroitin sulfate;

- bleeding, bleeding tendency;

- thrombophlebitis;

- pregnancy;

- breastfeeding period (at the time of treatment, breastfeeding should be stopped);

- children's age (data on efficacy and safety are not available).

Use during pregnancy and lactation

Use of the drug Injectran during pregnancy is contraindicated. In the case of the drug during the breastfeeding period, breastfeeding should be discontinued.

Special notes

It is recommended to increase the dose under the supervision of a physician for patients with overweight, gastric ulcer or duodenal ulcer, while taking diuretics, as well as at the beginning of treatment, if necessary, to accelerate the clinical response.

If allergic reactions develop or hemorrhage occurs, treatment should be discontinued.

Use in pediatrics

Data on the efficacy and safety of chondroitin sulfate in children are currently not available.

Influence on ability to drive vehicles and mechanisms

In the recommended dose range, the effect on concentration and speed of psychomotor reactions has not been established. When taken in high doses, it is recommended to be careful when driving vehicles, working with mechanisms and practicing other potentially hazardous activities that require high concentration of attention and speed of psychomotor reactions.


Currently, no cases of drug overdose have been reported on Injectran.

Symptoms: it can be assumed that if the daily dose is exceeded, the manifestations of the side effects of the drug may be enhanced.

Treatment: conducting symptomatic therapy.

Drug interaction

It is possible to enhance the effect of indirect anticoagulants, antiplatelet agents and fibrinolytics, which requires more frequent monitoring of blood coagulation parameters when used together.

Shows synergism of action with simultaneous use with Glucosamine and other chondroprotectors.

Terms and conditions of storage

The drug should be stored out of the reach of children, protected from light, at a temperature not exceeding 25 ° C. Shelf life - 3 years.

34 Items